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ABSTRACT: Metal-free magnetic resonance imaging (MRI)
agents could overcome the established toxicity associated with
metal-based agents in some patient populations and enable new
modes of functional MRI in vivo. Herein, we report nitroxide-
functionalized brush-arm star polymer organic radical contrast
agents (BASP-ORCAs) that overcome the low contrast and
poor in vivo stability associated with nitroxide-based MRI
contrast agents. As a consequence of their unique nano-
architectures, BASP-ORCAs possess per-nitroxide transverse
relaxivities up to ∼44-fold greater than common nitroxides,
exceptional stability in highly reducing environments, and low
toxicity. These features combine to provide for accumulation of
a suﬃcient concentration of BASP-ORCA in murine subcuta-
neous tumors up to 20 h following systemic administration such that MRI contrast on par with metal-based agents is observed.
BASP-ORCAs are, to our knowledge, the ﬁrst nitroxide MRI contrast agents capable of tumor imaging over long time periods
using clinical high-ﬁeld 1H MRI techniques.
■ INTRODUCTION
Among the many imaging modalities for medical diagnostics,
magnetic resonance imaging (MRI) is one of the most useful
thanks to its ability to noninvasively generate three-dimensional
detailed anatomical images with high spatial resolution while
not requiring an ionizing source and remaining insensitive to
depth.1−4 Current clinical MRI methods depict the spatial
distribution and chemical environment of water protons (1H)
within a region of interest (ROI); to enhance the diﬀerences
between native water 1H and ROIs, contrast agents are often
employed. These contrast agents are divided into two primary
classes: T1 contrast agents (e.g., paramagnetic metals such as
gadolinium or manganese) that aﬀord positive-contrast images
primarily by locally reducing the water 1H longitudinal
relaxation time (spin−lattice, T1), and T2 contrast agents
(e.g., superparamagnetic iron oxide nanoparticles) that aﬀord
negative-contrast images by locally reducing the water 1H
transverse relaxation time (spin−spin, T2).5,6 The correspond-
ing water 1H relaxivities (r1 and r2, respectively) of a contrast
agent characterize the extent to which the agent decreases the
T1 and T2 times of water
1H. Contrast agents with greater r1
and r2 values provide increased image contrast compared to
those with lower values at the same concentration.6,7
Most MRI contrast agents with large r1 and/or r2 values
contain metals that possess several unpaired electrons. For
example, small molecule8−13 and nanoparticle-based14−21
contrast agents featuring Gd, Mn, Fe-oxide, and other metals
have been reported to function as either T1 or T2 contrast
agents or both. Furthermore, metal-based contrast agents that
display advanced functions such as multimodal imag-
ing,8−10,12,13,17,20,21 enhanced target-speciﬁc accumula-
tion,14,18,19 and/or sensing8,11−14 have been developed. Despite
their unquestionable utility, metal-based contrast agents,
especially nanoparticle ones that tend to accumulate in
biological tissues, may present toxicity concerns in some
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patient populations. For example, Gd-based agents, perhaps the
most widely used T1 contrast agents in the clinic, are associated
with potentially lethal nephrogenic systemic ﬁbrosis, and they
have recently been linked to a rising prevalence of toxic Gd ions
in the environment.5,22−28 In addition, several T2 contrast
agents based on Fe-nanoparticles have been stopped from
further development or withdrawn from the market due to
safety concerns.29−32 Moreover, according to the FDA, Fe-
based products including ferumoxytol (Feraheme), the only
FDA-approved superparamagnetic iron oxide nanoparticle
currently available on the market, carry a risk of potentially
life-threatening allergic reactions.33−35 Thus, there is extensive
interest in the development of “metal-free” MRI contrast agents
that make use of entirely organic-based components. Such
agents could enable MRI in at-risk patient populations, and
they could potentially open new avenues for functional/
responsive MRI based on in vivo organic transformations.
Furthermore, organic nanoparticle contrast agents could
provide safe alternatives in MR imaging applications that may
require long-term tissue accumulation, such as tumor imaging.
Four main classes of metal-free MRI contrast agents have
been the most widely studied: paramagnetic nitroxide-based
organic radical contrast agents (ORCAs), hyperpolarized 13C
agents, 19F MRI contrast agents, and chemical exchange
saturation transfer (CEST) contrast agents. While 19F MRI
and CEST agents have undergone many advances in recent
Figure 1. (a) Chemical structures of BASP components studied in this work. (b) General brush-ﬁrst ROMP procedure. Branched MMs chex-MM
and Cy-MM are combined in the ratio j : 0.01j. This combination of MMs is exposed to 1.0 equiv of Grubbs III initiator to produce a living
bottlebrush with an average degree of polymerization (DP) = j + 0.01j = m. N equiv of acetal-XL is then added (in aliquots of 5 equiv of acetal-XL
every 5 min) to provide the ﬁnal BASP-ORCA. The properties of the BASP-ORCAs are deﬁned by their m and N values (Table 1).
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years,36−43 these approaches often suﬀer from low sensitivity,
and in some cases, require a high contrast agent concentration
(10−50 mM), long imaging times, and/or potentially harmful
high-intensity radio frequency ﬁelds. Hyperpolarized 13C
agents, on the other hand, can theoretically aﬀord up to 105
sensitivity improvements; nevertheless, issues including short
hyperpolarization lifetimes that lead to limited imaging times,
complexity in terms of the chemistry and instrumentation
required for generation of the hyperpolarized agent, and a
rather small substrate scope remain major challenges.44−46
Furthermore, 19F MRI, CEST, and hyperpolarized 13C agents
rely on imaging mechanisms that are not currently common in
the clinic.44−51 In contrast, nitroxide ORCAs rely on standard
water relaxation mechanisms to achieve MRI contrast; they
could in principle be immediately translated to clinical
applications. However, several key challenges limit the clinical
feasibility of nitroxide ORCAs. First, nitroxide radicals only
possess one unpaired electron. As a result, compared to metal-
based contrast agents such as Gd3+ (seven unpaired electrons)
or Mn2+ (ﬁve unpaired electrons), nitroxide ORCAs inherently
suﬀer from much lower water 1H relaxivity. One strategy to
achieve higher molecular relaxivity is to use a poly(nitroxide)
where the relatively low per nitroxide relaxivity is multiplied by
the number of nitroxides bound to a polymer scaﬀold. The
second major limitation of nitroxide ORCAs is that they are
typically reduced rapidly in vivo (half-lives on the order of
minutes) to diamagnetic hydroxylamines, thus rendering them
ineﬀective as contrast agents shortly after injection.52−55 Initial
eﬀorts to utilize nitroxides as MRI contrast agents exposed
these shortcomings,56,57 and though their rapid bioreduction
Table 1. Characterization Data for BASP-ORCAs and Control Compounds
composition diameter relaxivity
name m N Dh/nm DTEM/nm r1/mM
−1 s−1 r2/mM
−1 s−1 notes
3-CPa 0.15 0.17
chex-MMb 0.21 0.30
chex-dendrimera 0.44 0.86
chex-bottlebrushb 55.55 17b n.d. 0.32 0.82
BASP-ORCA 5.05 20 31 ± 2 n.d. 0.27 6.92 poor solubility (<10 mg/mL)
BASP-ORCA 5.05 30 49 ± 6 n.d. 0.53 7.11 poor solubility (<10 mg/mL)
BASP-ORCA1 7.07 20 31 ± 4 37 ± 7 0.41 4.67 good solubility (>50 mg/mL)
BASP-ORCA 7.07 30 36 ± 3 n.d. 0.35 7.40 poor solubility (<10 mg/mL)
BASP-ORCA 9.99 15 28 ± 3 38 ± 10 0.33 2.90 low relaxivity
BASP-ORCA 9.99 30 33 ± 4 39 ± 10 0.37 4.52 low relaxivity
aFrom refs 52 and 53. bFrom ref 80.
Figure 2. (a) Transmission electron microscopy image of BASP-ORCA1 (DTEM = 37 ± 7 nm) after being negatively stained with uranyl acetate; the
reported diameter (DTEM) represents the mean and standard deviation of >150 individual particle measurements. (b) Electron paramagnetic
resonance (EPR) spectra for BASP-ORCA1 and chex-MM. (c) T1 and T2-weighted MRI phantoms for BASP-ORCA1, chex-MM, PBS buﬀer, chex-
bottlebrush, and a PEG-BASP lacking chex. The concentration of chex-containing samples (BASP-ORCA1, chex-MM, and chex-bottlebrush)
ranges from 1 mM to 4 mM chex. The concentration of PEG-BASP lacking chex ranges from 6 mg/mL to 21 mg/mL, which is equivalent to the
mass per volume concentration range of BASP-ORCA1.
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has been cleverly exploited to enable redox-mapping in vitro
and in vivo,58−62 an in vivo-stable nitroxide ORCA that allows
for longitudinal studies over clinically meaningful time scales
following systemic administration has yet to be developed.
Macromolecular nitroxide ORCAs with long-term in vivo
stability could be particularly useful for tumor imaging.
Nanoparticles of suitable size (∼10−200 nm) are known to
passively accumulate in tumors, especially in murine models, via
the enhanced permeation and retention eﬀect, but hours to tens
of hours are often needed to reach maximal accumulation.63−69
To our knowledge, there are no nitroxide-based molecules or
materials with demonstrated capability to provide in vivo MRI
contrast after such long times. This problem is exacerbated in
murine models where imaging is often used for preclinical
studies of disease development: murine tissues contain higher
levels of metabolic antioxidants, which lead to faster nitroxide
reduction rates.70,71 Thus, the development of stable nitroxide-
based macromolecular ORCAs with high relaxivities could open
a new arena of MRI applications, whereby the accumulation of
contrast agents in diseased tissues could be monitored by MRI
without oﬀ-site toxicity concerns.55,72,73 Moreover, the
synthetic versatility of polymeric materials could facilitate
future image-guided drug delivery strategies.
Herein, we report the design, synthesis, and biological
evaluation of a new class of nitroxide macromoleculesbrush-
arm star polymer ORCAs (BASP-ORCAs)with unique
structures that are designed to overcome the aforementioned
challenges associated with tumor MRI with nitroxide-based
contrast agents. BASP-ORCAs contain a high concentration of
reduction-resistant nitroxide groups bound in an interlayer
between a poly(ethylene glycol) (PEG) shell and a polyacetal
core. Due to their shielded and dense nitroxide layer, yet
hydrophilic PEGylated nanostructures, BASP-ORCAs simulta-
neously possess the highest known water 1H transverse
relaxivities and stabilities for nitroxide ORCAs. In addition,
the modularity of BASP synthesis was exploited to install near-
infrared ﬂuorophores into BASP-ORCAs and thereby achieve
near-infrared ﬂuorescence (NIRF) imaging in concert with
MRI. Leveraging this combination of features, BASP-ORCAs
were successfully employed for longitudinal MR and NIRF
imaging of tumors with MRI contrast enhancement on par with
metal-based contrast agents observed up to 1 day following
systemic administration, which has, to our knowledge, never
been achieved with a paramagnetic organic agent. Notably,
though previous studies on nitroxide MRI contrast agents
focused on T1‑weighted imaging, BASP-ORCAs operate most
eﬀectively as T2 contrast agents, which is advantageous given
that high-ﬁeld instruments are being increasingly adopted in the
clinic, and r2 often remains similar or increases with magnetic
ﬁeld strength.74 Thus, BASP-ORCAs not only overcome the
challenges that have plagued all previous nitroxide-based MRI
contrast agents, and thereby facilitate the ﬁrst longitudinal
imaging of tumors with a nitroxide ORCA, but they are also
naturally amenable to current and future clinical high-ﬁeld MRI
instruments.
■ RESULTS AND DISCUSSION
BASP-ORCA Design and Synthesis. One of the most
common ways to increase the relaxivity of MRI contrast agents
(including nitroxides) involves attaching them to a rigid
macromolecular scaﬀold.6,47,52,53,75−78 For example, Rajca and
co-workers appended a spirocyclohexyl nitroxide derivative
(“chex”)79 to the surface of dendrimers to produce chex-
dendrimer ORCAs where the per-chex r1 was 0.42 mM
−1 s−1
compared to r1 = 0.14 mM
−1 s−1 for the model nitroxide 3-
carboxy-2,2,5,5-tetramethyl-l-pyrrolidinyloxy (3-CP).52,53 In a
later study, we appended chex to the core of PEGylated
branched-bottlebrush polymers.80 The resulting “chex-bottle-
brush” had a per-chex r1 of 0.32 mM
−1 s−1, which was
Figure 3. (a) EPR spectra for BASP-ORCA1 1, 40, and 180 min following exposure to 20 equiv of sodium ascorbate (Asc) per nitroxide. (b)
Ascorbate reduction kinetics for BASP-ORCA1, chex-bottlebrush, and chex-MM. (c) Cy5.5 emission at 700 nm in response to Asc and glutathione
(GSH); the reported values represent the mean and standard error of the mean (SEM) (n = 3).
Figure 4. (a) In vivo NIRF images of NCR nude mouse before and 20
h after injection of BASP-ORCA1 (see Supporting Information for
details). (b) Ex vivo NIRF images of selected organs (see Supporting
Information for details). Units of radiant eﬃciency:
μ
p / sec /cm / sr
W / cm
2
2 .
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approximately 50% greater than the chex-macromonomer used
to synthesize these polymers (chex-MM, Figure 1a). In this
system, r2 also increased from 0.30 mM
−1 s−1 for chex-MM to
0.82 mM−1 s−1 for the chex-bottlebrush polymer, thus
demonstrating that increasing the macromolecular size and
chex density leads to increases in both r1 and r2, with a greater
increase in r2.
80 In an eﬀort to further increase these relaxivity
values, we sought to incorporate chex into our BASP
macromolecules wherein the nitroxides would be bound at a
rigid core−shell interface.80−83 On the basis of this novel
structure compared to previous systems, we hypothesized that
BASPs could provide enhanced relaxivity and nitroxide stability
potentially making tumor imaging in vivo possible. Moreover,
the control and robustness of BASP synthesis would enable the
scalable production of BASP-ORCAs with optimal sizes for
tumor accumulation, which is diﬃcult with previous macro-
molecular systems such as dendrimers and bottlebrush
polymers.84−86
BASP-ORCAs were synthesized by brush-ﬁrst ring-opening
metathesis polymerization (ROMP) as depicted in Figure
1.84,86−88 Norbornene-based branched macromonomers (MMs,
Figure 1a) featuring 3 kDa PEG and either chex (chex-MM) or
Cy5.5 dye (Cy-MM, Figure 1a) were copolymerized by
exposure to Grubbs third-generation bis-pyridine initiator89
(Grubbs III, Figure 1a; reaction stoichiometry: j equiv. chex-
MM to 0.01j Cy-MM to 1.0 Grubbs III) for 30 min (Figure
1b). The resulting living bottlebrush polymers with an average
degree of polymerization (DP) of ∼j + 0.01j = m were then
cross-linked via portionwise addition of N equiv of bis-
norbornene acetal cross-linker acetal-XL84 (Figure 1a) to the
reaction mixture to generate the desired BASP-ORCA (Figure
1b). With this method, the BASP-ORCA size is determined by
the MM to Grubbs III to acetal-XL ratios (i.e., m and N
values). Much less Cy-MM (0.01j) relative to chex-MM (j) was
used to bridge the diﬀerence in concentration requirements
between MRI (mM to μM) and NIRF (nM to pM).1,6
To identify optimal conditions for the synthesis of BASP-
ORCAs with narrow size distributions and average diameters of
∼25−40 nm, as well as high water solubility and relaxivity, we
screened m and N values from 5−10 and 15−30, respectively
(Table 1). Gel permeation chromatography (GPC) revealed
nearly quantitative MM-to-bottlebrush conversion as well as
Figure 5. (a) T2-weighted MR images of tumor bearing NCR nude mouse before (top row) and 20 h after (bottom row) injection of 0.16 mmol
chex/kg (“low dose”) of BASP-ORCA1. Each series of images corresponds to progressive slices in the z-axis through the tumor of the same mouse.
(b) T2-weighted MR images of tumor bearing NCR nude mouse before (top row) and 20 h after (bottom row) injection of 0.23 mmol chex/kg
(“high dose”) of BASP-ORCA1. Each series of images corresponds to progressive slices in the z-axis through the tumor of the same mouse. (c) T2-
weighted coronal MR images before (top) and 20 h after (bottom) injection of 0.23 mmol chex/kg (“high dose”) of BASP-ORCA1. (d) Percent
MRI contrast change at various times following BASP-ORCA1 injection compared to preinjection. Statistical comparisons (n = 3 for low dose
group; n = 4 for high dose group; reported values represent mean ± SEM) to preinjection images were made with a student t test: **P ≤ 0.05, ***P
≤ 0.001.
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≥85% bottlebrush-to-BASP conversion for all m and N values
(Figure S1). The BASP-ORCA diameters as determined by
dynamic light scattering (DLS) and transmission electron
microscopy (TEM) ranged from ∼28 to ∼49 nm (Table 1). In
general, for the same bottlebrush arm length (m), the BASP-
ORCA size increased with the amount of acetal-XL added (N).
In addition, the BASP-ORCA aqueous solubility (Table 1)
increased with m. A representative TEM image for the m = 7.07
and N = 20 BASP-ORCA (referred to as BASP-ORCA1
throughout the remainder of this work) is provided in Figure
2a. The aqueous solubility of BASP-ORCA1 was the highest
amongst the BASP-ORCAs prepared, and its hydrodynamic
diameter (Dh) of 31 ± 4 nm is suitable for extended in vivo
circulation and tumor accumulation.66−68
Characterization of BASP-ORCA Magnetic Properties.
Electron paramagnetic resonance spectroscopy (EPR) was used
to conﬁrm the presence of chex in BASP-ORCAs, as well as to
study the chex environment in BASP-ORCA1. The spin
concentrations were ≥85% for all BASP-ORCAs. The height-
normalized EPR spectra for BASP-ORCA1 and chex-MM80 are
shown in Figure 2b. The spectrum for BASP-ORCA1 is
signiﬁcantly broader than chex-MM, which is consistent with
the larger and more rigid BASP nanostructure where chex is
bound at the dense interface between the acetal cross-linker
core and the PEG shell (Figures 1b and 2b). The BASP-
ORCA1 spectrum was simulated using the procedure
developed by Budil, Freed, and co-workers90 (see Supporting
Information section A for details), which allows for character-
ization of the chex mobility in terms of the correlation time for
rotational diﬀusion (τ). The spectrum was best ﬁtted by
superimposing two computed components (Figure S3): 22%
corresponded to a relatively fast-moving nitroxide with τ = 0.2
ns, while 78% corresponded to a slow-moving nitroxide with τ
= 10.0 ns. The faster-moving component likely corresponds to
nitroxides that are furthest from the BASP-ORCA1 acetal core
(Figure 1b), while the slow-moving component corresponds to
nitroxides that are close to and/or entangled within the acetal
core. Notably, the τ of 10.0 ns measured for the slow
component in BASP-ORCA1 is quite large, which suggests that
a majority of the chex groups are in a rigid environment. For
comparison, in our previously reported chex-dendrimer
ORCAs,52,53 TEMPO-labeled bottlebrush polymers,81,82 and
BASPs,83 the largest τ measured was ∼1 ns.
Next, we evaluated the longitudinal (r1) and transverse (r2)
relaxivities of these BASP-ORCAs using a Bruker 7 T MRI
scanner. The per-chex r1 values as a function of m and N (Table
1) ranged from 0.27 to 0.53 mM−1 s−1; they were not
signiﬁcantly increased compared to Rajca’s chex-dendrimer and
our chex-bottlebrush polymers. However, the per-chex r2
values ranged from 2.90 to 7.40 mM−1 s−1, which is ∼3.5- to
∼9.0-fold greater than the per-chex r2 in our chex-bottlebrush
polymers and ∼17- to ∼44-fold greater than 3-CP (Table 1).80
BASP-ORCA1 displayed a per-chex r2 value of 4.67 mM
−1 s−1.
Though this value was not the highest we measured, we
selected BASP-ORCA1 for translation to biological studies
because it oﬀered the best balance of high relaxivity, solubility
(greater than 50 mg/mL, Table 1), and size. Given the number-
average molar mass of BASP-ORCA1 as determined by gel
permeation chromatography and static light scattering (Mn =
4.75 × 105 g/mol, Đ = 1.32), we estimate that each BASP-
ORCA1 particle contains an average of 92 chex groups. Thus,
the estimated average molecular r1 and r2 values for BASP-
ORCA1 are 37.6 mM−1 s−1 and 428.8 mM−1 s−1, respectively,
which are greater than those for the commonly used FDA-
approved Gd-based contrast agent Magnevist (r1 = 3.1 mM
−1
s−1 and r2 = 5.4 mM
−1 s−1 at 7 T) and iron-based nanoparticles
such as Feraheme (r1 = 3.1 mM
−1 s−1 and r2 = 68 mM
−1 s−1 at
7 T).91−94
MR phantom images of phosphate-buﬀered saline (PBS)
solutions of BASP-ORCA1, chex-MM, and our previously
reported chex-bottlebrush polymer at various chex concen-
trations (from 1 mM−4 mM chex) as well as a PEG-BASP that
lacks chex (at equivalent mass fractions to BASP-ORCA1) are
provided in (Figure 2c), along with images for “blank” PBS
buﬀer. The T1-weighted images for BASP-ORCA1, and chex-
bottlebrush polymer are not obviously diﬀerent, while the T2-
weighted images clearly show a large reduction in signal for
BASP-ORCA1. The PEG-BASP with no chex shows no
diﬀerence in contrast as a function of concentration, which
conﬁrms that chex is required to observe changes in image
contrast.
The data presented above demonstrate that the high
nitroxide density of BASP-ORCA1, which is a consequence
of its unique cross-linked multilayer nanostructure, aﬀords an
increased magnetization capability that leads to r2 enhance-
ment. This ﬁnding is consistent with reports where nitroxides
are utilized as magnetic catalysts for outer-sphere relaxation
processes.95−97 Most importantly, the exceptionally high r2 of
Figure 6. (a) EPR spectra obtained for homogenized tissue samples
collected for the same mice imaged in Figure 5 22 h following BASP-
ORCA1 injection. (b) Blue: Muscle-normalized concentration of chex
per gram of protein as obtained from EPR double integration of tissue
homogenates. Red: Muscle-normalized concentration of Cy5.5 in
tissue homogenates as obtained from NIRF imaging. Statistical
comparisons (n = 4; reported values represent mean ± SEM) to
muscle signal were made with a Student’s t test: *not signiﬁcant, **P
≤ 0.05, ***P ≤ 0.001.
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BASP-ORCA1 overcomes one of the major limitations of
nitroxide-based contrast agents: inherently low contrast.
Ascorbate Quenching Kinetics of BASP-ORCAs. As
discussed above, nitroxide-based ORCAs typically suﬀer from
rapid reduction to diamagnetic hydroxylamines under bio-
logically relevant conditions. Among the many potential
biological reducing agents, ascorbate (Asc) is known to play a
major role in in vivo nitroxide reduction,54,98,99 and Asc-induced
reduction can be ampliﬁed by glutathione (GSH).80,99 We
hypothesized that the rigid chex environment in our BASP-
ORCAs could help to lower the rate of chex reduction. To test
this hypothesis, we collected EPR spectra for BASP-ORCA1 at
various times following exposure to 20 equiv of Asc and 20
equiv of GSH per nitroxide (both reagents were present in 10
mM concentrations). EPR spectra collected 1, 40, and 180 min
after exposure to these conditions are provided in Figure 3a.
The changes in peak height as a function of time are indicative
of nitroxide reduction. The normalized peak height of the EPR
spectra are plotted versus time in Figure 3b. Reduction kinetics
data for our previous chex-bottlebrush polymers and chex-MM
are provided for comparison.80 In contrast to the chex-
bottlebrush and chex-MM samples, which both display an
initial rapid chex reduction phase in the ﬁrst hour, the
reduction of chex in BASP-ORCA1 was signiﬁcantly retarded
with nearly 85% remaining after 1 h, and 70% remaining after 3
h (compared to 65% and 57%, respectively, for the chex-
bottlebrush). On the basis of the integrated peak heights as a
function of time, the second-order rate constants for BASP-
ORCA1 reduction in the initial (ﬁrst 10 min) and late (>1 h)
stages of the reduction process were calculated: kearly = 0.0376
M−1 s−1 and klate ≈ 0.00672 M−1 s−1) (Table S1).
52,53,80
Simulations revealed that the EPR spectra collected during the
reduction process consisted of a “fast” and a “slow” component
(Figure S3). Interestingly, τ for the “fast” component remained
constant at 0.2 ns, while τ for the “slow” component became
increasingly larger with time (11.0 ns at 40 min and 13.2 ns at
180 min). Therefore, even after 3 h there persists an extremely
reduction resistant and slow moving nitroxide population. The
presence of these very stable nitroxides within BASP-ORCA1
may enable T2-weighted MRI over longer time scales than have
been possible with previous nitroxide contrast agents (vide
inf ra).
Fluorescence Properties of BASP-ORCAs. As noted
above, Cy5.5 was also incorporated into these BASP-ORCAs
(see Figure S4 for BASP-ORCA1 absorption and emission
spectra conﬁrming the presence of Cy5.5) in order to
simultaneously use NIRF as an imaging modality for
comparison to MRI. Nitroxides are well-known to quench
ﬂuorescence via catalysis of nonemissive photophysical
processes such as intersystem crossing. This quenching requires
close interaction between the nitroxide and the ﬂuorophore;
the systems with the greatest quenching typically feature the
nitroxide directly linked to the ﬂuorophore via π bonds (i.e.,
electronic conjugation).100−102 Given the fact that chex and
Cy5.5 are incorporated into BASP-ORCAs via two diﬀerent
macromonomers and that the mobility of chex is limited in
these constructs, we reasoned that Cy5.5 quenching would be
minimal; therefore, we could potentially use Cy5.5 emission as
a fairly constant descriptor of particle concentration regardless
of the extent of chex reduction.
To test this hypothesis, we exposed BASP-ORCA1 to a large
excess of Asc (40−120 equiv. to chex) in water, and monitored
the resulting Cy5.5 emission. In agreement with our expect-
ation, only a 25 ± 2% to 30 ± 2% increase in ﬂuorescence
emission was observed (Figure 3c). Moreover, addition of GSH
(60 equiv) as a coreductant along with 60 equiv of Asc gave
only a 35 ± 7% increase in ﬂuorescence. Taken together, these
data suggest that Cy5.5 ﬂuorescence is minimally quenched by
chex in BASP-ORCA1. For comparison, exposure of our
previously reported chex-bottlebrush polymer containing Cy5.5
to excess Asc or Asc+GSH led to 119 ± 5% and 250 ± 5%
increases in ﬂuorescence, respectively.80 Notably, the time
required to achieve a ﬂuorescence plateau varied signiﬁcantly
between BASP-ORCA1 (approximately 40 min) and our chex-
bottlebrush polymer (a few minutes). Collectively, these data
suggest that the BASP nanostructure provides greater steric
shielding and isolation of chex and Cy5.5 compared to the
chex-bottlebrush polymer.
In Vitro Cytotoxicity and in Vivo Gross Toxicity,
Pharmacokinetics (PK), and Biodistribution (BD) of
BASP-ORCA1 in Non-Tumor-Bearing Mice. Next, we
investigated the performance of BASP-ORCA1 in biological
assays. As discussed above, one potential advantage of ORCAs
is their low toxicity. To assess the toxicity of BASP-ORCA1, we
ﬁrst conducted in vitro human umbilical vein endothelial cell
(HUVEC) and HeLa cell viability assays. In these assays, the
cells were incubated with varied concentrations of BASP-
ORCA1 for 72 h. Cell viability was determined by the
CellTiter-Glo assay (Supplemental Figure S5). The half-
maximal inhibitory concentrations of BASP-ORCA1, i.e., the
concentrations that led to 50% cell death, were 1.5 mg/mL
(280 μM chex) and 4.5 mg/mL (830 μM chex) in HUVEC
and HeLa cells, respectively. These results conﬁrm that BASP-
ORCA1 induces negligible in vitro cytotoxicity at practical
concentrations.85,86 Next, the in vivo gross toxicity of BASP-
ORCA1 was assessed. Healthy BALB/c mice were adminis-
tered increasing doses (from 5 to 30 mg or 0.2 to 1.5 g/kg,
respectively) of BASP-ORCA1 via tail vein injection. The
animal body masses and behaviors were monitored over the
course of 30 days. Loss of ≥10% body mass is generally
considered to be a sign of unacceptable toxicity.103,104 As
shown in Figure S6, even the highest dose of BASP-ORCA1
(administered to n = 4 animals) induced no signiﬁcant decrease
in body mass, which suggests that these particles are well-
tolerated up to their solubility-limiting dose.
The pharmacokinetics (PK) and biodistribution (BD) of
BASP-ORCA1 were monitored in healthy, nontumor bearing
BALB/c mice (n = 3) using NIRF imaging (IVIS, Cy5.5 λex/λem
= 640/700 nm). For PK analysis, blood samples were collected
via cardiac puncture at various time points from 1 to 48 h.
Percent injected dose was plotted as a function of time (Figure
S7a). As is common for spherical PEGylated nanostructures,
BASP-ORCA1 exhibited a two-phase clearance behavior, with
an early distribution phase of ∼6 h, followed by a steady
elimination phase.67,86 Fitting the data presented in Figure S7a
with a standard two-compartment model yielded a blood
compartment half-life for BASP-ORCA1 of 10 h.105 This long
half-life is attributed to the nanoscale size of BASP-ORCA1,
which limits renal clearance, and its PEGylated corona.66,69
Consistent with these results and a plethora of studies on
PEGylated nanoparticles,65−69 BD analysis revealed that a
majority of BASP-ORCA1 accumulated in the liver, with
increasing accumulation over 72 h (Figure S7b). Less
accumulation in the kidney and negligible accumulation in
other tissues was observed. Fluorescence in extracted lung
tissue is attributed to a high concentration of BASP-ORCA1 in
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the blood. Notably, ﬂuorescence images of fecal samples
(Figure S7c) suggest that BASP-ORCA1 is ultimately cleared
from the body via excretion.
BASP-ORCA1 BD in Tumor-Bearing Mice. Given the
long circulation of BASP-ORCA1, we hypothesized that this
particle would passively accumulate in subcutaneous tumors
following systemic injection. To test this hypothesis, we ﬁrst
established a tumor model via subcutaneous injection of a
mixture of 2.0 × 106 lung carcinoma cells (A549, ATCC),
Matrigel, and PBS buﬀer into a hind ﬂank of NCR-NU mice (n
= 4). When the average tumor volume was ∼1 cm, BASP-
ORCA1 was administered at a dose of 0.23 mmol chex/kg (1.2
g BASP-ORCA1/kg) via tail vein injection. NIRF images
collected 20 h after administration indicated substantial tumor
accumulation of BASP-ORCA1, which is consistent with other
reports for PEGylated nanoparticles of similar size including
our related drug-conjugated BASPs (Figure 4a).65,66,69,86 Ex
vivo BD data were consistent with our studies on nontumor
bearing BALB/c mice (i.e., liver accumulation and persistence
in blood) with the addition of signiﬁcant tumor accumulation
(Figure 4b and Figure S8).
MRI and NIRF Imaging with BASP-ORCA1 in Tumor-
Bearing Mice. The low toxicity, long circulation half-life, and
tumor accumulation of BASP-ORCA1, along with its excep-
tional stability and relaxivity, suggested that this particle could
be suitable for MRI of tumors following systemic injection and
accumulation; a feat that, to our knowledge, has not yet been
achieved with ORCAs. Two groups of A459 tumor-bearing
NCR-NU mice were administered diﬀerent doses of BASP-
ORCA1 via tail-vein injection: the “low dose” group (n = 3)
received 0.16 mmol chex/kg (0.8 g BASP-ORCA1/kg), while
the “high dose” group (n = 4) received 0.23 mmol chex/kg (1.2
g BASP-ORCA1/kg). The mice were anaesthetized and MR
images were collected at various time points: 12, 16, and 20 h
postinjection for the low dose group and 20 h postinjection for
the high dose group. The images from each time point were
compared to images collected before BASP-ORCA1 injection.
Figures 5a shows T2-weighted false-colored images for a
selected mouse from the low dose group imaged before BASP-
ORCA1 injection (top row of images) and 20 h (bottom row
of images) after BASP-ORCA1 injection. From left-to-right the
images correspond to progressive slices of the same animal in
the z-axis with the tumor indicated with a yellow arrow in each
image. Figure 5b shows an analogous set of images for a
selected mouse from the high dose group. Contrast diﬀerences
between the preinjection and postinjection images can be
observed at both dose levels, with greater contrast observed in
the high dose animal (Figure 5b). Whole animal images
similarly revealed a clear diﬀerence in tumor contrast (Figure
5c, yellow arrows).
The percent negative contrast enhancement (i.e., the amount
of signal reduction) before and after BASP-ORCA1 admin-
istration was quantiﬁed by image analysis (Figure 5d). Signal
reductions ranging from 14 ± 2% to 16 ± 2% (P ≤ 0.05) were
observed for the 12 to 20 h time points in the low dose group
(Figure 5d, red bars). In the high dose group, a 24 ± 2% (P ≤
0.001) signal reduction was observed 20 h after BASP-ORCA1
administration (Figure 5d, blue bar). The BASP-ORCA1
dose−response eﬀect suggests that the observed contrast
diﬀerences between pre- and postinjection are due to
accumulation of BASP-ORCA1 in the tumors. Keeping in
mind that MRI phantoms revealed no observable contrast
enhancement for PEG-BASPs that lack chex (Figure 2c), these
MRI data imply that 20 h following injection there is a
suﬃcient concentration of chex radicals present on the BASP-
ORCA1 in the tumor to impart contrast. To conﬁrm the
presence of chex radicals in the tumors, the same mice that
were imaged by MRI were sacriﬁced 21 h after BASP-ORCA1
administration and their tissue homogenates and blood were
analyzed by EPR spectroscopy (Figure 6a). From these spectra,
the radical concentration per gram of protein in each tissue
sample, the latter obtained via a bicinchoninic acid assay
(BCA), was evaluated and normalized by the radical
concentration per gram of protein in muscle tissue (Figure
6b). In agreement with our MRI data, the concentration of free
radicals in the tumor was quite high after BASP-ORCA1
injection; the measured value of 0.25 ± 0.04 μmol chex/g
chex/g of protein corresponds to 4.5% of the injected dose of
chex radicals. Moreover, consistent with our in vivo NIRF
imaging results (vide supra), relatively high radical concen-
trations were observed in the liver and kidney, which suggests
that the clearance of BASP-ORCA1 proceeded mostly through
these organs. Notably, the murine liver contains a high
concentration of Asc (millimolar range); our observation of
radicals in the liver is further evidence of the extremely stable
nature of the chex units in BASP-ORCA1 (Note: in our
previous chex-bottlebrush polymers, there was very little chex
radical in the liver following 30 min and none observed after 24
h). A high chex concentration was also observed in the heart,
which is in accord with a long blood compartment half-life and
is consistent with our PK data obtained by NIRF imaging.
Finally, NIRF imaging of these homogenates provided
ﬂuorescence radiant eﬃciencies that were in good agreement
with our spin concentrations (Figure 6b), which suggests that
the chex radicals and Cy5.5 dyes are still colocalized within the
BASP-ORCA1 construct after biodistribution. Unlike our
previous chex-bottlebrush polymers, which displayed dramatic
increases in ﬂuorescence as chex was reduced, the signal
uniformity oﬀered by BASP-ORCA1 provides for straightfor-
ward multimodal conﬁrmation of BD.
To the best of our knowledge, BASP-ORCA1 is the ﬁrst
nitroxide MRI contrast agent capable of providing signiﬁcant
contrast 20 h after injection, which is a testament to its unique
structural features that combine optimal size for tumor
accumulation with a high nitroxide density and stability. To
set these results in context, we compared our data to recent
literature examples of MRI-contrast agents that rely on metals
to achieve tumor imaging following systemic administration.
For example, Kataoka and co-workers recently reported on a
new class of Gd-based nanoparticles (T1 contrast agents) for
MRI of tumors. In their study, a ∼40% contrast enhancement
(at 0.05 mmol Gd/kg iv dose) was observed 4 h following
injection into mice bearing subcutaneous C26 tumors. Notably,
the commercially available small molecule contrast agent Gd-
DTPA exhibited negligible contrast enhancement (at 0.23
mmol Gd/kg iv dose) after 4 h.16 This example highlights the
importance of a nanoparticle system for extended circulation
and tumor imaging. The same group reported Fe-based
nanoparticles (T2 contrast agents) for tumor imaging in a
similar murine model (subcutaneous C26 tumors). Here, an
approximately 25% contrast diﬀerence was observed 24 h
following intravenous administration of 0.45 mg Fe/kg.
Notably, less than 10% contrast enhancement was observed
using commercially available Resovist (at 0.45 mg Fe/kg
intravenous dose).15 It should be noted that the instrument
parameters used to obtain T2-weighted images in this work
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were similar to those used above in our studies; thus, our results
for BASP-ORCA1 are on par with recently reported nano-
particle MRI contrast agents that rely on metals to achieve
contrast.
■ CONCLUSION
We have developed a nitroxide-based macromolecular MRI
contrast agent BASP-ORCA1 that enables simultaneous
MRI and NIRF imaging in vivo over time scales suitable for
tumor imaging following systemic injection. BASP-ORCA1
addresses the two major challenges that have historically limited
nitroxide-based organic radical contrast agents for MRI: low
relaxivity and poor stability. These functions were made
possible by the brush-arm star polymer (BASP) nanostructure,
which places a dense layer of chex nitroxides at the interface
between a rigid poly(acetal) core and a hydrophilic PEG shell.
Altogether, BASP-ORCA1 displayed unprecedented per-nitro-
xide and per-molecule transverse relaxivities for organic radical
contrast agents, exceptional stability, high water solubility, low
in vitro and in vivo toxicity, and a long blood compartment half-
life. These features combined to facilitate the imaging of
subcutaneous tumors in mice 20 h after tail-vein injection,
providing contrast enhancements on par with commercial and
literature examples of metal-based contrast agents. This work
suggests that organic radicals can be viable alternatives to metal-
based MRI contrast agents, and sets the stage for the
development of theranostic systems that combine organic
radical contrast agents with therapeutic payloads to achieve
simultaneous tumor imaging and drug delivery without
concerns over long-term tissue accumulation of metals.
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